Activating mutations in human acute megakaryoblastic leukemia

Se'bastien Malinge, Christine Ragu, Veronique Della-Valle, Didier Pisani, Stefan N. Constantinescu, Christelle Perez, Jean Luc Villeval, Dirk Reinhardt, Judith Landman-Parker, Lucienne Michaux, Nicole Dastugue, Andre' Baruchel, William Vainchenker, Jean Pierre Bourquin, Virginie Penard-Lacronique, Olivier A. Bernard

    Research output: Contribution to journalArticlepeer-review

    132 Citations (Scopus)

    Abstract

    Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia (AMKL), we performed sequence analyses of a subset of oncogenes known to be activated in human myeloid and myeloproliferative disorders. In a series of human AMKL samples from both Down syndrome and non-Down syndrome patients, mutations were identified within KIT, FLT3, JAK2, JAK3, and MPL genes, with a higher frequency in DS than in non-DS patients. The novel mutations were analyzed using BaF3 cells, showing that JAK3 mutations were activating mutations. Finally, we report a novel constitutively active MPL mutant, MPLT487A, observed in a non-Down syndrome childhood AMKL that induces a myeloproliferative disease in mouse bone marrow transplantation assay.

    Original languageEnglish
    Pages (from-to)4220-4226
    Number of pages7
    JournalBlood
    Volume112
    Issue number10
    DOIs
    Publication statusPublished - 15 Nov 2008

    Cite this